Astegolimab Reduces COPD Exacerbations in Broad Patient Population

Managing Frequent Exacerbations in COPD

Chronic obstructive pulmonary disease (COPD) remains a major driver of morbidity, with acute exacerbations significantly worsening quality of life and increasing mortality risk [1, 2, 3]. While foundational treatments like bronchodilators are essential, they often prove insufficient for patients with severe disease or those who experience frequent exacerbations [4]. This has spurred the development of biological therapies, such as monoclonal antibodies, that target specific inflammatory pathways underlying COPD pathogenesis, with the goal of reducing the burden of these acute events [1, 4, 5, 6, 3].

Investigating Astegolimab: An Anti-ST2 Monoclonal Antibody

A recent investigation centered on astegolimab, a monoclonal antibody designed to target the ST2 receptor. By binding to ST2, astegolimab blocks the signaling of interleukin-33 (IL-33), a key cytokine involved in type 2 inflammatory responses that can drive airway inflammation and exacerbations in some patients with chronic obstructive pulmonary disease (COPD). The study's objective was to determine if this targeted inhibition could reduce the frequency of exacerbations in a high-risk patient group. To achieve this, researchers conducted a prespecified pooled analysis, a method that combines data from multiple similar trials, in this case the pivotal ALIENTO and ARNASA studies, to generate more robust and statistically powerful conclusions.

Trial Design and Patient Characteristics

The ALIENTO and ARNASA trials were structured as randomized, double-blind, placebo-controlled studies to minimize bias. The investigators enrolled a broad cohort of individuals with COPD who were current or former smokers and had a documented history of frequent exacerbations. A notable feature of the trial design was the inclusion of a clinically heterogeneous population, meaning patients were enrolled regardless of their blood eosinophil count or the presence of chronic bronchitis. This approach is significant because it reflects the diverse patient population seen in routine clinical practice, enhancing the potential generalizability of the findings. A total of 2682 participants were included in the final pooled intent-to-treat population. They were randomized in a 1:1:1 ratio to receive either astegolimab 476 mg every 2 weeks, astegolimab 476 mg every 4 weeks, or a placebo for 52 weeks, all as an add-on to their existing optimized maintenance therapy.

Primary and Secondary Endpoints

The trials' primary measure of success was the annualized rate of moderate to severe chronic obstructive pulmonary disease (COPD) exacerbations, a clinically meaningful endpoint that reflects events requiring medical intervention. Secondary endpoints included the annualized rate of severe exacerbations, which are events leading to hospitalization or an emergency department visit. To ensure statistical integrity, the analysis followed a hierarchical testing plan. This rigorous method requires the primary endpoint to be met before formal statistical testing of key secondary endpoints is performed, a process known as gating. This approach protects against an inflated risk of false positive findings when multiple outcomes are assessed.

Significant Reduction in Exacerbation Rates

The pooled analysis revealed a statistically significant benefit for astegolimab in reducing the primary endpoint. The group receiving astegolimab 476 mg every 2 weeks demonstrated a 15% reduction in the annualized rate of moderate to severe exacerbations compared to placebo (adjusted rate ratio 0.85; 95% CI, 0.76 to 0.96; P = .0077). The every 4-week dosing schedule also showed a significant benefit, with a 12% reduction in the same endpoint (rate ratio 0.88; 95% CI, 0.78 to 0.99; P = .0265). Following the successful primary endpoint, the analysis of secondary outcomes showed a nominally significant reduction in the rate of severe exacerbations for the more frequent dosing schedule. The astegolimab every 2-week regimen was associated with a 32% relative reduction in severe exacerbations (rate ratio 0.68; 95% CI, 0.52 to 0.87; P = .0028), a finding of high clinical relevance given the impact of these events on patient morbidity and healthcare utilization.

Safety Profile and Clinical Implications

Across the pooled population, astegolimab was reported to be well tolerated, a critical consideration for any long-term therapy in patients who often have multiple comorbidities. The findings from the ALIENTO and ARNASA trials suggest that astegolimab, particularly when administered every 2 weeks, can reduce the rate of moderate to severe exacerbations in patients with chronic obstructive pulmonary disease (COPD) and a history of frequent events. The efficacy observed in a clinically heterogeneous population, including patients without elevated eosinophils or chronic bronchitis, is noteworthy. It suggests that targeting the IL-33/ST2 pathway may offer a therapeutic benefit to a broader group of COPD patients than some existing biologics that are restricted to specific inflammatory phenotypes. The trial registration numbers for ALIENTO and ARNASA are ClinicalTrials.gov: NCT05037929 and NCT05595642, respectively.

References

1. Mohamed MM, Kamel G, Charbek E. Role of Monoclonal Antibodies in the Management of Eosinophilic Chronic Obstructive Pulmonary Disease: A Meta-Analysis of Randomized Controlled Trials. Annals of the American Thoracic Society. 2024. doi:10.1513/annalsats.202406-597oc

2. Mohamed MMG, Kamel G, Charbek E. Role of Monoclonal Antibodies in the Management of Eosinophilic Chronic Obstructive Pulmonary Disease: A Meta-analysis of Randomized Controlled Trials.. Annals of the American Thoracic Society. 2025. doi:10.1513/AnnalsATS.202406-597OC

3. Singh D, Higham A, Mathioudakis AG, Beech A. Chronic Obstructive Pulmonary Disease (COPD): Developments in Pharmacological Treatments. Drugs. 2025. doi:10.1007/s40265-025-02188-8

4. Ziojła-Lisowska K, Kuzio A, Cieplińska A. Treatment of COPD with a particular focus on biological therapy: a systematic review. Quality in Sport. 2024. doi:10.12775/qs.2024.17.53022

5. Xiong Y, Hu J, Tang H, Zhao Z, Liu L. Network meta-analysis of the efficacy and safety of monoclonal antibodies and traditional conventional dichotomous agents for chronic obstructive pulmonary disease. Frontiers in Medicine. 2024. doi:10.3389/fmed.2024.1334442

6. Wu Y, Huang M, Zhong J, et al. The clinical efficacy of type 2 monoclonal antibodies in eosinophil-associated chronic airway diseases: a meta-analysis. Frontiers in Immunology. 2023. doi:10.3389/fimmu.2023.1089710